Physician profile
Ivan Aldea
NPI 1356516058
$4,955.86
in general payments reported to CMS, 2019-2025
25 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $672 · 2021: $619 · 2022: $682 · 2023: $1,078 · 2024: $604 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $918.05 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $687.96 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $418.16 | 2019-2024 | Rexulti |
| Alkermes, INC. | $372.84 | 2019-2023 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $351.27 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $301.67 | 2019-2023 | Uzedy, Austedo |
| Ironshore Pharmaceuticals INC. | $284.13 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $240.88 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $227.18 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $192.17 | 2020-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $171.78 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.31 | 2020-2023 | |
| Tris Pharma INC | $106.87 | 2020-2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $102.30 | 2020-2023 | Trintellix |
| Collegium Pharmaceutical, INC. | $86.95 | 2025 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $59.99 | 2020 | |
| Avanir Pharmaceuticals, INC. | $57.92 | 2019-2021 | |
| Bausch Health US, LLC | $57.71 | 2019-2021 | |
| Almatica Pharma LLC | $47.18 | 2024 | Loreev Xr |
| Shire North American Group INC | $30.36 | 2019 | |
| Axsome Therapeutics, INC. | $27.37 | 2023 | Sunosi |
| Allergan, INC. | $22.82 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.96 | 2024 | Cobenfy |
| Sage Therapeutics, LLC | $18.11 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Aldea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.